Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Licenses Data from Genaissance s STRENGTH Statin Study

NEW YORK, Sept. 11 (GenomeWeb News) - AstraZeneca has licensed data from Genaissance Pharmaceutical's so-called STRENGTH study, the company said today.

Terms of the agreement call for AstraZeneca to receive non-exclusive access to the database, which it will use for "a limited period."

This STRENGTH study -- or Statin Response Examined by Genetic Haplotype Markers -- followed more than 400 patients and showed that gene mutations influence a patient's response to the statin class of antihypercholesterolemia drugs.

The 16-week study prospectively analyzed for an association between an individual's haplotypes and the effectiveness of three statins -- atorvastatin, pravastatin, and simvastatin -- in reducing LDL- cholesterol.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.